Supernus Pharmaceuticals Inc

Latest Results (07.08.2024):

Net Sales Growth

Supernus Pharmaceuticals Inc. reported a significant increase in net sales for Qelbree® in the second quarter of 2024, with a 92% rise compared to the same period in 2023. The net sales for Qelbree® reached $59.4 million in the second quarter and $104.5 million for the first six months of 2024.

Total Revenues

Total revenues for Supernus Pharmaceuticals Inc. in the second quarter of 2024 were $168.3 million, marking a 24% increase compared to the same period in 2023. For the first six months of 2024, total revenues were $312.0 million, up from $289.3 million in the same period in 2023.

Operating Income

Supernus Pharmaceuticals Inc. reported an operating income of $22.6 million for the second quarter of 2024, compared to an operating loss of $(17.6) million in the same period in 2023. For the first six months of 2024, operating income was $19.4 million, a significant improvement from the $(12.4) million loss in the first half of 2023.

Adjusted Operating Earnings

Adjusted operating earnings (non-GAAP) for Supernus Pharmaceuticals Inc. were $45.5 million in the second quarter of 2024, compared to $10.0 million in the same period in 2023. For the first six months of 2024, adjusted operating earnings were $67.7 million, up from $40.5 million in the first half of 2023.

Full Year Guidance

Supernus Pharmaceuticals Inc. has raised its full-year 2024 financial guidance. The company now expects total revenues to be between $600 million and $625 million, up from the previous guidance of $580 million to $620 million. Additionally, the guidance for adjusted operating earnings (non-GAAP) has been increased to a range of $100 million to $125 million.